Primo Biotechnology

About Primo Biotechnology

Primo Biotechnology, founded in 2021 by Dr. Joe Yeh and Dr. Ya-Yao Huang, is a Taiwanese radiopharmaceutical company focused on precision cancer care. Dr. Huang, the CEO, has an extensive background in radiopharmaceuticals, having served as the head of the cyclotron center at National Taiwan University Hospital. Dr. Yeh serves as the Chairman and is also the CEO and Chairman of aetherAI.

The company develops and manufactures radiopharmaceuticals for molecular imaging and targeted therapy. Its business model centers on the research and development of novel radioligand theranostics, supported by its own drug development, clinical translation, and GMP manufacturing capabilities. Primo Biotechnology also operates as a Contract Research Organization (CRO) and a Contract Development and Manufacturing Organization (CDMO), providing one-stop services for clinical trials using radiopharmaceuticals. This includes scientific consulting, technical support, and assistance with regulatory applications. In April 2025, the company's Taoyuan facility received PIC/S GMP and GDP certifications.

A key product is Radelumin ([18F]PSMA-1007), a diagnostic radiopharmaceutical for prostate cancer, for which Primo is the manufacturing and distribution partner in Taiwan for ABX advanced biochemical compounds GmbH. The company is also developing its own pipeline candidates, PB011 and PB012, for other cancer indications. Additionally, through a partnership with SHINE Technologies, Primo has the exclusive distribution rights in Taiwan for Ilumira (n.c.a. lutetium-177), a therapeutic isotope, with sales rights in Japan, South Korea, and Singapore. The company also offers pre-clinical research services, including animal models and in-vivo imaging to support drug development.

Since its inception, Primo Biotechnology has raised over NT$500 million. This includes an angel round, a seed round led by AVA Angels, and a NT$220 million Series A round completed in July 2025. The company has stated its intention to pursue an IPO in 2026 to further expand its research and development capabilities.